Asthma
Conditions
Interventions
None listed
Sponsors
Maruyama Atsushi
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients aged >= 18 years at enrollment 2.Untreated asthma patients defined as newly diagnosed asthma or patients with asthma without any asthma treatments for at least 6 months prior to enrollment 3.Patients who meet the following criteria for mild or moderate persistent asthma as defined for untreated asthma by JGL2024 4.Patients who initiate the middle to high dose ICS/LABA treatmenteither on the day of enrollment or within 2 days prior to enrollment 5.Patients who gave informed consent on the website
Exclusion criteria
Exclusion criteria: 1.Patients who initiate ICS/LABA/LAMA treatment, including single inhaler triple therapy or multi-inhaler triple therapy at enrollment 2.Patients who are prescribed systemic corticosteroids at enrollment 3.Patients who have any respiratory infection episode within one month prior to enrollment 4.Patients who are diagnosed with chronic obstructive pulmonary disease (COPD) at enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Odds ratio between the odds of poorly controlled (ACT total score < 23) patients in the cohort A(Patients with high symptom frequency ) and that in cohort B(Patients with low symptom frequency ) at week 4. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Odds ratio between the odds of poorly controlled (ACT total score 3) at week 4, 8 and 12 3.Mean of the AHQ-33 total score at enrollment, week 4, 8 and 12, and mean change in the AHQ-33 total score from enrollment at week 4, 8 and 12 | — |
Contacts
Public ContactYoichi Tamai
AstraZeneca K.K.
Outcome results
None listed